ABOS - NASDAQ

Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc.

ABOS·NASDAQ

$2.29

-0.65%
HealthcareBiotechnology

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$138.71M
EPS-2.0000
P/E Ratio-1.15
Earnings Date08/11/2026

Available Earnings Call Transcripts

Select a year and quarter to view the full transcript.

Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc. Earnings Call Transcripts

ABOS · NASDAQ

Related Guides

Blog Categories

Continue your ABOS research with focused valuation guides.

Forecasting

Compare management guidance with modeled outcomes.

Risk Analysis

Track estimate risk, misses, and downside scenarios.

Reference

Review analyst process and transcript interpretation.

Value Investing

Anchor quarterly narrative to intrinsic value discipline.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.